Uterine fibroids: Safety and efficacy of ultrasound-guided microwave ablation

Key clinical point: Ultrasound-guided microwave ablation (MWA) is a safe and effective minimally invasive treatment strategy for symptomatic uterine fibroids.

Major finding: In patients treated with MWA, uterine fibroid symptom scores decreased significantly (reduction rate, 65.9%; P less than .0001) and the quality of life scores (increasing rate, 72.0%; P less than .0001) and hemoglobin levels increased significantly (increasing rate, 30.3%; P less than .0001) from baseline to follow-up. No major adverse events were reported.

Study details: A meta-analysis of 10 studies involving 671 patients.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source: Liu L et al. J Minim Invasive Gynecol. 2021 Jun 28. doi: 10.1016/j.jmig.2021.06.020.

Key clinical point: Ultrasound-guided microwave ablation (MWA) is a safe and effective minimally invasive treatment strategy for symptomatic uterine fibroids.

Major finding: In patients treated with MWA, uterine fibroid symptom scores decreased significantly (reduction rate, 65.9%; P less than .0001) and the quality of life scores (increasing rate, 72.0%; P less than .0001) and hemoglobin levels increased significantly (increasing rate, 30.3%; P less than .0001) from baseline to follow-up. No major adverse events were reported.

Study details: A meta-analysis of 10 studies involving 671 patients.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source: Liu L et al. J Minim Invasive Gynecol. 2021 Jun 28. doi: 10.1016/j.jmig.2021.06.020.

Key clinical point: Ultrasound-guided microwave ablation (MWA) is a safe and effective minimally invasive treatment strategy for symptomatic uterine fibroids.

Major finding: In patients treated with MWA, uterine fibroid symptom scores decreased significantly (reduction rate, 65.9%; P less than .0001) and the quality of life scores (increasing rate, 72.0%; P less than .0001) and hemoglobin levels increased significantly (increasing rate, 30.3%; P less than .0001) from baseline to follow-up. No major adverse events were reported.

Study details: A meta-analysis of 10 studies involving 671 patients.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source: Liu L et al. J Minim Invasive Gynecol. 2021 Jun 28. doi: 10.1016/j.jmig.2021.06.020.